Abstract

Objective: In small case-control studies, obesity was associated with worse vitamin D status. Our aim was to assess the association of adiposity (anthropometric measures as well as dual energy x-ray absorptiometry) with serum 25-hydroxyvitamin D (25-OH-D) and serum PTH levels in a large population-based study including older men and women.

Methods: Subjects were participants of the Longitudinal Aging Study Amsterdam and were aged 65 yr and older. In 453 participants, serum 25-OH-D and PTH were determined, and body mass index, waist circumference, waist to hip ratio, sum of skin folds, and total body fat percentage by dual energy x-ray absorptiometry were measured.

Results: After adjustment for potential confounders, higher body mass index, waist circumference, and sum of skin folds were statistically significantly associated with lower 25-OH-D (standardized β values were −0.136, −0.137, and −0.140, respectively; all P < 0.05) and with higher PTH (0.166, 0.113, and 0.114, respectively; all P < 0.05). Total body fat percentage was more strongly associated with 25-OH-D and PTH (−0.261 and 0.287, respectively; both P < 0.001) compared with anthropometric measures. Total body fat percentage remained associated with 25-OH-D after adjustment for PTH, and with PTH after adjustment for 25-OH-D.

Conclusion: Precisely measured total body fat is inversely associated with 25-OH-D levels and is positively associated with PTH levels. The associations were weaker if anthropometric measures were used, indicating a specific role of adipose tissue. Regardless of the possible underlying mechanisms, it may be relevant to take adiposity into account when assessing vitamin D requirements.

VITAMIN D IS well known for its essential role in bone metabolism and calcium homeostasis (1). However, it has become increasingly clear that the vitamin D endocrine system has additional physiological functions (2).

Evidence is increasing that the vitamin D endocrine system is related to obesity. Obesity has been found to be associated with lower levels of serum 25-hydroxyvitamin D (25-OH-D) (311) and higher levels of serum PTH (3, 8, 9, 12, 13). Underlying causes that have been suggested are less sun exposure in obese subjects due to limited mobility or clothing habits and a higher storage of vitamin D in adipose tissue (4, 11). However, overweight may also be the consequence of poor vitamin D status. Vitamin D is an important determinant of serum PTH levels, and increased PTH promotes calcium influx into the adipocytes. In these cells, intracellular calcium enhances lipogenesis, and therefore, PTH excess may promote weight gain (14, 15).

The relation between body fat content and serum 25-OH-D or PTH has usually been investigated in relatively small (case-control) studies (35, 79, 11). Furthermore, not many studies used direct measures of body fatness. The aim of the present study was to assess the association of adiposity with serum 25-OH-D and PTH levels in a large population-based study including older men and women.

Subjects and Methods

Study sample

The Longitudinal Aging Study Amsterdam is an ongoing cohort study of the predictors and consequences of changes in autonomy and well-being in an aging population in The Netherlands. The sampling and data collection procedures have been described in detail previously (16). Briefly, a random sample of older men and women (aged 55–85 yr), stratified by age, sex, urbanization, and expected 5-yr mortality, was drawn from the population registers of 11 municipalities in areas in the west, northeast, and south of The Netherlands. In total, 3107 subjects participated in the baseline examination (1992/1993).

In 1995/1996, a second examination took place; participants were then aged 65 yr and older. After an interview at home, participants were invited for a medical interview at one of the research centers, where blood samples were obtained. Respondents living in the west (n = 685) were also invited for a whole body dual energy x-ray absorptiometry (DXA) scan, which was obtained for 518 respondents. The study sample for the present study included subjects in whom a DXA scan was performed and serum 25-OH-D and PTH levels were available (n = 514). Subjects with missing anthropometric information (n = 61) were excluded. Therefore, our final study sample consisted of 453 subjects who were predominantly Caucasian (99%). Informed consent was obtained from all respondents. The study was approved by the medical ethics committee of the Vrije University Medical Center.

Measurements

Blood samples were obtained and centrifuged in the morning. Subjects were allowed to have tea and toast, but no dairy products. The serum samples were stored at −70 C. Serum PTH was measured by an immunoradiometric assay (Incstar Corp., Stillwater, MN), and serum 25-OH-D was determined according to a competitive binding protein assay (Nichols Diagnostics, San Juan Capistrano, CA). The interassay coefficients of variation were 12 and 10%, respectively. The analyses were carried out at the Endocrine Laboratory of the Vrije University Medical Center.

The assessments of body mass index (BMI; kilograms per meter squared), waist circumference (centimeters), and waist to hip circumference ratio (WHR) have been described previously (17). The thicknesses of skin folds (millimeters) at the triceps, biceps, suprailiac, and subscapular were measured in triplicate, and the sum of the mean thickness of each skin fold was used in the analyses.

Total body fat (kilograms) was measured by whole body DXA (software version V5.67A, QDR 2000, Hologic, Inc., Waltham, MA). The system software first determines bone mineral content and soft tissue compartments. Then soft tissue is further separated into fat and fat-free soft tissue masses. The total body fat percentage (percentage) was calculated as (total body fat/total body weight) × 100.

Because vitamin D status is partly dependent on sunlight exposure, we adjusted for the season of data collection. Because mild renal impairment could affect PTH and 25-OH-D homeostasis, we also adjusted for serum creatinine. The level of physical activity (minutes per day) was estimated by a validated interview-administered questionnaire for older subjects (18). Smoking status was classified as smoker or nonsmoker (cigarettes, tobacco, cigar, and pipe), and alcohol use was classified as light, moderate, excessive, or very excessive, based on the alcohol consumption index of Garretsen (19).

Statistical analyses

All analyses were performed using SPSS for Windows (version 11.0.1, SPSS, Inc., Chicago, IL). Multiple linear regression analyses were performed to study the associations between body composition variables (independent variables) and serum 25-OH-D or PTH levels (dependent variables). Because the distribution of serum PTH was skewed, we used the logarithmic transformation. We adjusted for potential confounders by adding them to the regression models. Effect modification by sex was evaluated by stratified analyses and tested by adding product terms of body composition variables × sex to the regression models. To facilitate direct comparisons of the strengths of the associations, the results of the regression models are reported as standardized β values. A standardized β of 0.2 indicates that if the independent variable increases by 1 sd, the dependent variable increases by 0.2 sd.

Results

Table 1 shows the characteristics of the study participants according to sex-specific quartiles of total body fat percentage. Total body fat was inversely associated with serum 25-OH-D and positively with serum PTH levels in both sexes (all P < 0.05). In 8.0% of the men and 14.4% of the women, the serum 25-OH-D level was less than 10 ng/ml (25 nmol/liter; deficient status), and 44.7% of the men and 56.1% of the women had serum 25-OH-D levels below 20 ng/ml (50 nmol/liter; insufficient status). Anthropometric measures were also inversely related to 25-OH-D, but this crude association was only statistically significant for BMI and waist circumference in women (P < 0.05). BMI, waist circumference, and sum of skin folds were statistically significantly and positively associated with serum PTH in women only (all P < 0.05).

TABLE 1.

Characteristics of participants according to quartiles of total body fat percentage (TBF%) for men and women separately

 MenWomen
Quartile 1 n = 59Quartile 2 n = 59Quartile 3 n = 60Quartile 4 n = 59Quartile 1 n = 54Quartile 2 n = 54Quartile 3 n = 54Quartile 4 n = 54
Range in TBF%8.5–23.923.9–28.428.6–32.832.9–43.422.3–38.438.6–42.943.0–48.148.2–59.9
25-OH-D (ng/ml)23.8 ± 9.622.6 ± 9.022.5 ± 8.918.6 ± 7.221.2 ± 8.820.0 ± 10.019.3 ± 7.616.1 ± 7.1
PTH (pg/ml)29.4 (23.7–38.6)31.9 (24.8–42.6)32.7 (27.1–41.0)37.8 (27.2–47.6)28.0 (23.2–35.4)28.9 (21.7–38.9)31.2 (24.3–36.3)40.1 (28.1–50.8)
Adiposity measures        
    Total body fat (kg)12.8 ± 3.420.1 ± 2.924.7 ± 3.130.5 ± 4.819.7 ± 4.927.2 ± 3.431.6 ± 4.541.8 ± 6.3
    TBF%19.2 ± 4.126.6 ± 1.230.6 ± 1.335.7 ± 2.532.8 ± 4.740.8 ± 1.445.2 ± 1.351.4 ± 2.6
    BMI (kg/m2)22.4 ± 2.225.5 ± 2.726.9 ± 1.828.4 ± 2.422.8 ± 2.626.1 ± 2.427.6 ± 2.932.0 ± 3.9
    WHR0.91 ± 0.050.98 ± 0.051.00 ± 0.041.01 ± 0.050.87 ± 0.090.87 ± 0.090.88 ± 0.060.91 ± 0.06
    Waist circumference (cm)86.5 ± 6.696.7 ± 6.6102.1 ± 6.1107.2 ± 7.782.3 ± 9.188.1 ± 8.592.4 ± 8.3103.9 ± 9.5
    Sum of skin folds (mm)37.9 ± 9.853.8 ± 12.859.0 ± 9.470.8 ± 13.454.5 ± 15.170.1 ± 12.980.7 ± 14.992.5 ± 13.9
Possible confounders        
    Age (yr)76.4 ± 6.274.7 ± 6.474.7 ± 6.576.6 ± 6.775.2 ± 6.273.7 ± 6.573.6 ± 6.175.8 ± 5.9
    Physical activity (min/d)124.8 ± 88.5149.7 ± 108.3134.3 ± 89.5116.8 ± 92.8182.6 ± 118.5184.3 ± 81.8174.3 ± 97.9159.2 ± 80.6
    Alcohol use (%)        
        No10.28.515.013.624.122.214.835.2
        Light55.955.938.347.553.751.961.153.7
        Moderate28.822.033.323.722.224.122.29.3
        (Very) excessive5.113.613.315.3 1.91.91.9
    Smoking (%)30.527.118.323.724.114.816.711.1
 MenWomen
Quartile 1 n = 59Quartile 2 n = 59Quartile 3 n = 60Quartile 4 n = 59Quartile 1 n = 54Quartile 2 n = 54Quartile 3 n = 54Quartile 4 n = 54
Range in TBF%8.5–23.923.9–28.428.6–32.832.9–43.422.3–38.438.6–42.943.0–48.148.2–59.9
25-OH-D (ng/ml)23.8 ± 9.622.6 ± 9.022.5 ± 8.918.6 ± 7.221.2 ± 8.820.0 ± 10.019.3 ± 7.616.1 ± 7.1
PTH (pg/ml)29.4 (23.7–38.6)31.9 (24.8–42.6)32.7 (27.1–41.0)37.8 (27.2–47.6)28.0 (23.2–35.4)28.9 (21.7–38.9)31.2 (24.3–36.3)40.1 (28.1–50.8)
Adiposity measures        
    Total body fat (kg)12.8 ± 3.420.1 ± 2.924.7 ± 3.130.5 ± 4.819.7 ± 4.927.2 ± 3.431.6 ± 4.541.8 ± 6.3
    TBF%19.2 ± 4.126.6 ± 1.230.6 ± 1.335.7 ± 2.532.8 ± 4.740.8 ± 1.445.2 ± 1.351.4 ± 2.6
    BMI (kg/m2)22.4 ± 2.225.5 ± 2.726.9 ± 1.828.4 ± 2.422.8 ± 2.626.1 ± 2.427.6 ± 2.932.0 ± 3.9
    WHR0.91 ± 0.050.98 ± 0.051.00 ± 0.041.01 ± 0.050.87 ± 0.090.87 ± 0.090.88 ± 0.060.91 ± 0.06
    Waist circumference (cm)86.5 ± 6.696.7 ± 6.6102.1 ± 6.1107.2 ± 7.782.3 ± 9.188.1 ± 8.592.4 ± 8.3103.9 ± 9.5
    Sum of skin folds (mm)37.9 ± 9.853.8 ± 12.859.0 ± 9.470.8 ± 13.454.5 ± 15.170.1 ± 12.980.7 ± 14.992.5 ± 13.9
Possible confounders        
    Age (yr)76.4 ± 6.274.7 ± 6.474.7 ± 6.576.6 ± 6.775.2 ± 6.273.7 ± 6.573.6 ± 6.175.8 ± 5.9
    Physical activity (min/d)124.8 ± 88.5149.7 ± 108.3134.3 ± 89.5116.8 ± 92.8182.6 ± 118.5184.3 ± 81.8174.3 ± 97.9159.2 ± 80.6
    Alcohol use (%)        
        No10.28.515.013.624.122.214.835.2
        Light55.955.938.347.553.751.961.153.7
        Moderate28.822.033.323.722.224.122.29.3
        (Very) excessive5.113.613.315.3 1.91.91.9
    Smoking (%)30.527.118.323.724.114.816.711.1

Data are the mean ± sd, median (interquartile range), or percentage. To convert to SI units, multiply by 2.496 for 25-OH-D (nanomoles per liter) and by 0.105 for PTH (picomoles per liter).

TABLE 1.

Characteristics of participants according to quartiles of total body fat percentage (TBF%) for men and women separately

 MenWomen
Quartile 1 n = 59Quartile 2 n = 59Quartile 3 n = 60Quartile 4 n = 59Quartile 1 n = 54Quartile 2 n = 54Quartile 3 n = 54Quartile 4 n = 54
Range in TBF%8.5–23.923.9–28.428.6–32.832.9–43.422.3–38.438.6–42.943.0–48.148.2–59.9
25-OH-D (ng/ml)23.8 ± 9.622.6 ± 9.022.5 ± 8.918.6 ± 7.221.2 ± 8.820.0 ± 10.019.3 ± 7.616.1 ± 7.1
PTH (pg/ml)29.4 (23.7–38.6)31.9 (24.8–42.6)32.7 (27.1–41.0)37.8 (27.2–47.6)28.0 (23.2–35.4)28.9 (21.7–38.9)31.2 (24.3–36.3)40.1 (28.1–50.8)
Adiposity measures        
    Total body fat (kg)12.8 ± 3.420.1 ± 2.924.7 ± 3.130.5 ± 4.819.7 ± 4.927.2 ± 3.431.6 ± 4.541.8 ± 6.3
    TBF%19.2 ± 4.126.6 ± 1.230.6 ± 1.335.7 ± 2.532.8 ± 4.740.8 ± 1.445.2 ± 1.351.4 ± 2.6
    BMI (kg/m2)22.4 ± 2.225.5 ± 2.726.9 ± 1.828.4 ± 2.422.8 ± 2.626.1 ± 2.427.6 ± 2.932.0 ± 3.9
    WHR0.91 ± 0.050.98 ± 0.051.00 ± 0.041.01 ± 0.050.87 ± 0.090.87 ± 0.090.88 ± 0.060.91 ± 0.06
    Waist circumference (cm)86.5 ± 6.696.7 ± 6.6102.1 ± 6.1107.2 ± 7.782.3 ± 9.188.1 ± 8.592.4 ± 8.3103.9 ± 9.5
    Sum of skin folds (mm)37.9 ± 9.853.8 ± 12.859.0 ± 9.470.8 ± 13.454.5 ± 15.170.1 ± 12.980.7 ± 14.992.5 ± 13.9
Possible confounders        
    Age (yr)76.4 ± 6.274.7 ± 6.474.7 ± 6.576.6 ± 6.775.2 ± 6.273.7 ± 6.573.6 ± 6.175.8 ± 5.9
    Physical activity (min/d)124.8 ± 88.5149.7 ± 108.3134.3 ± 89.5116.8 ± 92.8182.6 ± 118.5184.3 ± 81.8174.3 ± 97.9159.2 ± 80.6
    Alcohol use (%)        
        No10.28.515.013.624.122.214.835.2
        Light55.955.938.347.553.751.961.153.7
        Moderate28.822.033.323.722.224.122.29.3
        (Very) excessive5.113.613.315.3 1.91.91.9
    Smoking (%)30.527.118.323.724.114.816.711.1
 MenWomen
Quartile 1 n = 59Quartile 2 n = 59Quartile 3 n = 60Quartile 4 n = 59Quartile 1 n = 54Quartile 2 n = 54Quartile 3 n = 54Quartile 4 n = 54
Range in TBF%8.5–23.923.9–28.428.6–32.832.9–43.422.3–38.438.6–42.943.0–48.148.2–59.9
25-OH-D (ng/ml)23.8 ± 9.622.6 ± 9.022.5 ± 8.918.6 ± 7.221.2 ± 8.820.0 ± 10.019.3 ± 7.616.1 ± 7.1
PTH (pg/ml)29.4 (23.7–38.6)31.9 (24.8–42.6)32.7 (27.1–41.0)37.8 (27.2–47.6)28.0 (23.2–35.4)28.9 (21.7–38.9)31.2 (24.3–36.3)40.1 (28.1–50.8)
Adiposity measures        
    Total body fat (kg)12.8 ± 3.420.1 ± 2.924.7 ± 3.130.5 ± 4.819.7 ± 4.927.2 ± 3.431.6 ± 4.541.8 ± 6.3
    TBF%19.2 ± 4.126.6 ± 1.230.6 ± 1.335.7 ± 2.532.8 ± 4.740.8 ± 1.445.2 ± 1.351.4 ± 2.6
    BMI (kg/m2)22.4 ± 2.225.5 ± 2.726.9 ± 1.828.4 ± 2.422.8 ± 2.626.1 ± 2.427.6 ± 2.932.0 ± 3.9
    WHR0.91 ± 0.050.98 ± 0.051.00 ± 0.041.01 ± 0.050.87 ± 0.090.87 ± 0.090.88 ± 0.060.91 ± 0.06
    Waist circumference (cm)86.5 ± 6.696.7 ± 6.6102.1 ± 6.1107.2 ± 7.782.3 ± 9.188.1 ± 8.592.4 ± 8.3103.9 ± 9.5
    Sum of skin folds (mm)37.9 ± 9.853.8 ± 12.859.0 ± 9.470.8 ± 13.454.5 ± 15.170.1 ± 12.980.7 ± 14.992.5 ± 13.9
Possible confounders        
    Age (yr)76.4 ± 6.274.7 ± 6.474.7 ± 6.576.6 ± 6.775.2 ± 6.273.7 ± 6.573.6 ± 6.175.8 ± 5.9
    Physical activity (min/d)124.8 ± 88.5149.7 ± 108.3134.3 ± 89.5116.8 ± 92.8182.6 ± 118.5184.3 ± 81.8174.3 ± 97.9159.2 ± 80.6
    Alcohol use (%)        
        No10.28.515.013.624.122.214.835.2
        Light55.955.938.347.553.751.961.153.7
        Moderate28.822.033.323.722.224.122.29.3
        (Very) excessive5.113.613.315.3 1.91.91.9
    Smoking (%)30.527.118.323.724.114.816.711.1

Data are the mean ± sd, median (interquartile range), or percentage. To convert to SI units, multiply by 2.496 for 25-OH-D (nanomoles per liter) and by 0.105 for PTH (picomoles per liter).

After adjustment for age, season, sex, and smoking, higher BMI, waist circumference, and sum of skin folds were statistically significantly associated with lower 25-OH-D and higher PTH concentrations (Table 2, model 1). The associations of DXA total body fat (either in kilograms or as a percentage) with serum 25-OH-D and PTH levels were stronger than the associations of the anthropometric measures and were statistically significant for both men and women (Table 2 and Fig. 1).

Fig. 1.

Mean 25-OH-D levels (±se; upper panel) and mean ln-PTH levels (±se; lower panel) plotted against the mean total body fat percentage (TBF) within sex-specific quartiles of total body fat percentage, adjusted for age, season, and smoking.

TABLE 2.

Associations [standardized β values (sB)] of body composition variables (continuous, independent variable) in relation to 25-OH-D (continuous, dependent variable) and in relation to PTH, for both sexes combined and for men and women separately

 Model 1Model 2
Both sexesMenWomenBoth sexesMenWomen
sBPsBPsBPsBPsBPsBP
25-OH-D            
    BMI−0.1360.001−0.0800.182−0.1810.003−0.0960.020−0.0750.203−0.0930.122
    WHR−0.0510.317−0.0810.176−0.0020.969−0.0370.453−0.0720.2140.0190.752
    WC−0.1370.002−0.1250.036−0.1380.025−0.1090.010−0.1170.045−0.0790.182
    Sum of skin folds−0.1400.004−0.1290.033−0.1190.054−0.1110.016−0.1290.029−0.0560.343
    TBF−0.1850.000−0.1520.012−0.1860.002−0.1370.003−0.1300.028−0.1100.063
    TBF%−0.2610.000−0.1700.004−0.1970.001−0.1940.001−0.1420.016−0.1230.038
PTH            
    BMI0.1660.0000.0260.6850.2980.0000.1260.0050.0060.9210.2350.000
    WHR0.0550.3250.0390.5430.0660.3520.0390.4680.0190.7640.0650.327
    WC0.1130.0190.0380.5530.1930.0050.0710.1260.0070.9110.1410.029
    Sum of skin folds0.1140.0310.0020.9720.2010.0030.0710.163−0.0300.6530.1560.016
    TBF0.1990.0000.1080.0960.2550.0000.1460.0030.0720.2620.1890.003
    TBF%0.2870.0000.1470.0210.2560.0000.2140.0010.1080.0880.1870.004
 Model 1Model 2
Both sexesMenWomenBoth sexesMenWomen
sBPsBPsBPsBPsBPsBP
25-OH-D            
    BMI−0.1360.001−0.0800.182−0.1810.003−0.0960.020−0.0750.203−0.0930.122
    WHR−0.0510.317−0.0810.176−0.0020.969−0.0370.453−0.0720.2140.0190.752
    WC−0.1370.002−0.1250.036−0.1380.025−0.1090.010−0.1170.045−0.0790.182
    Sum of skin folds−0.1400.004−0.1290.033−0.1190.054−0.1110.016−0.1290.029−0.0560.343
    TBF−0.1850.000−0.1520.012−0.1860.002−0.1370.003−0.1300.028−0.1100.063
    TBF%−0.2610.000−0.1700.004−0.1970.001−0.1940.001−0.1420.016−0.1230.038
PTH            
    BMI0.1660.0000.0260.6850.2980.0000.1260.0050.0060.9210.2350.000
    WHR0.0550.3250.0390.5430.0660.3520.0390.4680.0190.7640.0650.327
    WC0.1130.0190.0380.5530.1930.0050.0710.1260.0070.9110.1410.029
    Sum of skin folds0.1140.0310.0020.9720.2010.0030.0710.163−0.0300.6530.1560.016
    TBF0.1990.0000.1080.0960.2550.0000.1460.0030.0720.2620.1890.003
    TBF%0.2870.0000.1470.0210.2560.0000.2140.0010.1080.0880.1870.004

TBF, Total body fat; WC, waist circumference. Model 1, Adjusted for age, season, smoking, and also for sex if men and women were combined. Model 2, Model 1 additionally adjusted for PTH or 25-OH-D.

TABLE 2.

Associations [standardized β values (sB)] of body composition variables (continuous, independent variable) in relation to 25-OH-D (continuous, dependent variable) and in relation to PTH, for both sexes combined and for men and women separately

 Model 1Model 2
Both sexesMenWomenBoth sexesMenWomen
sBPsBPsBPsBPsBPsBP
25-OH-D            
    BMI−0.1360.001−0.0800.182−0.1810.003−0.0960.020−0.0750.203−0.0930.122
    WHR−0.0510.317−0.0810.176−0.0020.969−0.0370.453−0.0720.2140.0190.752
    WC−0.1370.002−0.1250.036−0.1380.025−0.1090.010−0.1170.045−0.0790.182
    Sum of skin folds−0.1400.004−0.1290.033−0.1190.054−0.1110.016−0.1290.029−0.0560.343
    TBF−0.1850.000−0.1520.012−0.1860.002−0.1370.003−0.1300.028−0.1100.063
    TBF%−0.2610.000−0.1700.004−0.1970.001−0.1940.001−0.1420.016−0.1230.038
PTH            
    BMI0.1660.0000.0260.6850.2980.0000.1260.0050.0060.9210.2350.000
    WHR0.0550.3250.0390.5430.0660.3520.0390.4680.0190.7640.0650.327
    WC0.1130.0190.0380.5530.1930.0050.0710.1260.0070.9110.1410.029
    Sum of skin folds0.1140.0310.0020.9720.2010.0030.0710.163−0.0300.6530.1560.016
    TBF0.1990.0000.1080.0960.2550.0000.1460.0030.0720.2620.1890.003
    TBF%0.2870.0000.1470.0210.2560.0000.2140.0010.1080.0880.1870.004
 Model 1Model 2
Both sexesMenWomenBoth sexesMenWomen
sBPsBPsBPsBPsBPsBP
25-OH-D            
    BMI−0.1360.001−0.0800.182−0.1810.003−0.0960.020−0.0750.203−0.0930.122
    WHR−0.0510.317−0.0810.176−0.0020.969−0.0370.453−0.0720.2140.0190.752
    WC−0.1370.002−0.1250.036−0.1380.025−0.1090.010−0.1170.045−0.0790.182
    Sum of skin folds−0.1400.004−0.1290.033−0.1190.054−0.1110.016−0.1290.029−0.0560.343
    TBF−0.1850.000−0.1520.012−0.1860.002−0.1370.003−0.1300.028−0.1100.063
    TBF%−0.2610.000−0.1700.004−0.1970.001−0.1940.001−0.1420.016−0.1230.038
PTH            
    BMI0.1660.0000.0260.6850.2980.0000.1260.0050.0060.9210.2350.000
    WHR0.0550.3250.0390.5430.0660.3520.0390.4680.0190.7640.0650.327
    WC0.1130.0190.0380.5530.1930.0050.0710.1260.0070.9110.1410.029
    Sum of skin folds0.1140.0310.0020.9720.2010.0030.0710.163−0.0300.6530.1560.016
    TBF0.1990.0000.1080.0960.2550.0000.1460.0030.0720.2620.1890.003
    TBF%0.2870.0000.1470.0210.2560.0000.2140.0010.1080.0880.1870.004

TBF, Total body fat; WC, waist circumference. Model 1, Adjusted for age, season, smoking, and also for sex if men and women were combined. Model 2, Model 1 additionally adjusted for PTH or 25-OH-D.

When analyses were performed for men and women separately, the associations of body composition variables with serum PTH tended to be stronger in women than in men, except for WHR. When interaction by sex was tested, it was not statistically significant for 25-OH-D, and it was only borderline statistically significant for sum of skin folds and PTH (P = 0.062). However, when comparing associations between men and women, substantial differences were observed (Table 2).

Additional adjustment of the associations for serum creatinine, alcohol intake, or physical activity level (total activity or outdoor activities only) did not appreciably change the associations (data not shown). After adjustment for smoking, the associations became stronger (change of >10%); therefore, we presented the associations after adjustment for smoking. The Pearson correlation coefficient between serum 25-OH-D and ln-PTH was −0.30. Additional adjustment for PTH considerably weakened the associations between measures of body fatness and 25-OH-D, and additional adjustment for 25-OH-D considerably weakened the associations between measures of body fatness and PTH (Table 2, model 2). Most associations with DXA-measured total body fat, however, remained statistically significant.

When we distinguished trunk fat from leg fat and added them simultaneously to the regression models as two separate independent variables, leg fat was a strong determinant of 25-OH-D, whereas trunk fat was not significantly associated with 25-OH-D [standardized β value, −0.161 (P = 0.017) and −0.054 (P = 0.341), respectively]. In contrast, trunk fat was a strong determinant of PTH levels, whereas leg fat was not significantly associated with PTH [standardized β value, 0.155 (P = 0.013) and 0.055 (P = 0.457), respectively].

Discussion

This report shows a strong inverse association between total body fatness and serum 25-OH-D levels and a strong positive association between body fatness and serum PTH levels in older men and women, independent of age, sex, season, study region, and smoking. The associations were weaker if anthropometric estimates were used compared with DXA total body fat percentage.

In the 1980s, small case-control studies showed that serum 25-OH-D levels were lower in obese subjects compared with nonobese individuals (3, 4, 20), and serum PTH levels were higher (3), which was confirmed in more recent studies (5, 9, 11). In observational studies, similar associations of BMI with 25-OH-D or PTH were shown (7, 8, 12, 13), but these were not always statistically significant (6, 10, 21). In our sample we found statistically significant associations between BMI and 25-OH-D and between BMI and PTH levels. However, the associations of these hormones with total body fat percentage by DXA were even stronger, which was also found in younger women (mean age, 47 yr) (10). These results indicate that it is adiposity, and not simply body weight or BMI, that is associated with serum 25-OH-D and PTH concentrations. Previous studies have probably underestimated the associations by using anthropometric measures.

In reports from the 1970s (22, 23), it was suggested that the association between serum 25-OH-D and obesity could be explained by an increased storage of 25-OH-D in adipose tissue in obese subjects. Rosenstreich et al. (22) supplemented rats with radiolabeled vitamin D, and adipose tissue was found to be the major storage site. Mawer et al. (23) found similar results in human tissues after injection of radioactive cholecalciferol. In a more recent study by Wortsman et al. (11), the capacity of the skin to produce vitamin D was not altered in obesity. However, the increase in serum vitamin D3 after sun exposure was 57% less in obese compared with nonobese subjects. The increase in serum vitamin D3 after oral supplementation was similar in obese and nonobese subjects. This supports the hypothesis of a decreased release of endogenously produced vitamin D into the circulation due to more storage in sc fat in obese subjects (11). The fact that in our study leg fat was more strongly related to 25-OH-D levels compared with trunk fat supports the idea that endogenously produced vitamin D is particularly stored in the sc fat depot (11).

Recently, evidence has been accumulating that obesity can also be the consequence of a low vitamin D status. Increased PTH levels, of which serum 25-OH-D is an important determinant, promote calcium influx into the adipocytes. In these cells intracellular calcium enhances lipogenesis; therefore, PTH excess may promote weight gain (14, 15). The fact that PTH was also associated with adiposity after adjustment for 25-OH-D could suggest that PTH, also independently of 25-OH-D, contributes to the development of adiposity. The observation that a higher dietary intake of calcium, which is related to lower PTH levels, is related to lower body weight (24) and less weight gain (25) also fits the hypothesis of high PTH levels as a cause of obesity. Subjects with primary hyperparathyroidism, who have increased PTH levels, were also markedly heavier than age-matched controls (26, 27). In addition, calcium supplementation, which also decreases PTH levels, resulted in a greater weight loss compared with placebo treatment (25, 28). These intervention studies suggest a modest, but causal, relation between serum PTH and weight change. Serum 25-OH-D is an important determinant of PTH levels, and interventions have shown that supplementation with α-calcidol resulted in modest, but significant, weight loss (29, 30). In our study, however, the 25-OH-D level was also related to adiposity independently of PTH levels.

In conclusion, in a large population-based study, including both men and women, we found that total body fat percentage measured by DXA is strongly associated with serum 25-OH-D and PTH levels, independently of age, sex, season, or smoking. The associations were weaker if anthropometric measures were used, indicating a specific role of adipose tissue. Long-term longitudinal studies with repeated measures of vitamin D and PTH should be performed to explore the direction of effects underlying our observations. Considering the possible role of vitamin D and PTH in the development of cancer, muscle weakness, insulin resistance, diabetes, and cardiovascular disease (3133), it may be relevant to take adiposity into account when assessing vitamin D requirements.

Acknowledgments

This study is based on data collected in the context of the Longitudinal Aging Study Amsterdam, which is largely funded by the Ministry of Health, Welfare, and Sports of The Netherlands. R.M.v.D. was supported by The Netherlands Organization for Scientific Research (ZonMw VENI Grant 916.46.077).

Abbreviations:

     
  • BMI,

    Body mass index;

  •  
  • DXA,

    dual energy x-ray absorptiometry;

  •  
  • 25-OH-D,

    25-hydroxyvitamin D;

  •  
  • WHR,

    waist to hip ratio.

References

1

Lips
P
2001
Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.
Endocr Rev
22
:
477
501

2

Holick
MF
2003
Vitamin D: a millenium perspective.
J Cell Biochem
88
:
296
307

3

Bell
NH
,
Epstein
S
,
Greene
A
,
Shary
J
,
Oexmann
MJ
,
Shaw
S
1985
Evidence for alteration of the vitamin D-endocrine system in obese subjects.
J Clin Invest
76
:
370
373

4

Liel
Y
,
Ulmer
E
,
Shary
J
,
Hollis
BW
,
Bell
NH
1988
Low circulating vitamin D in obesity.
Calcif Tissue Int
43
:
199
201

5

Buffington
C
,
Walker
B
,
Cowan Jr
GS
,
Scruggs
D
1993
Vitamin D deficiency in the morbidly obese.
Obes Surg
3
:
421
424

6

Need
AG
,
Morris
HA
,
Horowitz
M
,
Nordin
C
1993
Effects of skin thickness, age, body fat, and sunlight on serum 25-hydroxyvitamin D.
Am J Clin Nutr
58
:
882
885

7

Chiu
KC
,
Chu
A
,
Go
VL
,
Saad
MF
2004
Hypovitaminosis D is associated with insulin resistance and β cell dysfunction.
Am J Clin Nutr
79
:
820
825

8

Stein
MS
,
Flicker
L
,
Scherer
SC
,
Paton
LM
,
O’Brien
ML
,
Walton
SC
,
Chick
P
,
Di Carlantonio
M
,
Zajac
JD
,
Wark
JD
2001
Relationships with serum parathyroid hormone in old institutionalized subjects.
Clin Endocrinol (Oxf)
54
:
583
592

9

Parikh
SJ
,
Edelman
M
,
Uwaifo
GI
,
Freedman
RJ
,
Semega-Janneh
M
,
Reynolds
J
,
Yanovski
JA
2004
The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults.
J Clin Endocrinol Metab
89
:
1196
1199

10

Arunabh
S
,
Pollack
S
,
Yeh
J
,
Aloia
JF
2003
Body fat content and 25-hydroxyvitamin D levels in healthy women.
J Clin Endocrinol Metab
88
:
157
161

11

Wortsman
J
,
Matsuoka
LY
,
Chen
TC
,
Lu
Z
,
Holick
MF
2000
Decreased bioavailability of vitamin D in obesity.
Am J Clin Nutr
72
:
690
693

12

Kamycheva
E
,
Sundsfjord
J
,
Jorde
R
2004
Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study.
Eur J Endocrinol
151
:
167
172

13

Wareham
NJ
,
Byrne
CD
,
Carr
C
,
Day
NE
,
Boucher
BJ
,
Hales
CN
1997
Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality.
Metabolism
46
:
1171
1177

14

Zemel
MB
2002
Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications.
J Am Coll Nutr
21
:
146
S–151S

15

McCarty
MF
,
Thomas
CA
2003
PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight.
Med Hypotheses
61
:
535
542

16

Deeg
DJ
,
van Tilburg
T
,
Smit
JH
,
de Leeuw
ED
2002
Attrition in the Longitudinal Aging Study Amsterdam. The effect of differential inclusion in side studies.
J Clin Epidemiol
55
:
319
328

17

Visser
M
,
Launer
LJ
,
Deurenberg
P
,
Deeg
DJ
1997
Total and sports activity in older men and women: relation with body fat distribution.
Am J Epidemiol
145
:
752
761

18

Stel
VS
,
Smit
JH
,
Pluijm
SM
,
Visser
M
,
Deeg
DJ
,
Lips
P
2004
Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer.
J Clin Epidemiol
57
:
252
258

19

Garretsen
HFL
1983
Probleemdrinken, prevalentiebepaling, beinvloedende factoren en preventiemogelijkhede, Theoretische overwegingen en onderzoek in Rotterdam (in Dutch).
Lisse, The Netherlands
:
Swets & Zeitlinger

20

Compston
JE
,
Vedi
S
,
Ledger
JE
,
Webb
A
,
Gazet
JC
,
Pilkington
TR
1981
Vitamin D status and bone histomorphometry in gross obesity.
Am J Clin Nutr
34
:
2359
2363

21

Scragg
R
,
Holdaway
I
,
Singh
V
,
Metcalf
P
,
Baker
J
,
Dryson
E
1995
Serum 25-hydroxyvitamin D3 is related to physical activity and ethnicity but not obesity in a multicultural workforce.
Aust NZ J Med
25
:
218
223

22

Rosenstreich
SJ
,
Rich
C
,
Volwiler
W
1971
Deposition in and release of vitamin D3 from body fat: evidence for a storage site in the rat.
J Clin Invest
50
:
679
687

23

Mawer
EB
,
Backhouse
J
,
Holman
CA
,
Lumb
GA
,
Stanbury
SW
1972
The distribution and storage of vitamin D and its metabolites in human tissues.
Clin Sci
43
:
413
431

24

Zemel
MB
,
Shi
H
,
Greer
B
,
Dirienzo
D
,
Zemel
PC
2000
Regulation of adiposity by dietary calcium.
FASEB J
14
:
1132
1138

25

Davies
KM
,
Heaney
RP
,
Recker
RR
,
Lappe
JM
,
Barger-Lux
MJ
,
Rafferty
K
,
Hinders
S
2000
Calcium intake and body weight.
J Clin Endocrinol Metab
85
:
4635
4638

26

Grey
AB
,
Evans
MC
,
Stapleton
JP
,
Reid
IR
1994
Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism.
Ann Intern Med
121
:
745
749

27

Bolland
MJ
,
Grey
AB
,
Gamble
GD
,
Reid
IR
2005
Association between primary hyperparathyroidism and increased body weight: a meta-analysis.
J Clin Endocrinol Metab
90
:
1525
1530

28

Heaney
RP
,
Davies
KM
,
Barger-Lux
MJ
2002
Calcium and weight: clinical studies.
J Am Coll Nutr
21
:
152
S–155S

29

Lind
L
,
Pollare
T
,
Hvarfner
A
,
Lithell
H
,
Sorensen
OH
,
Ljunghall
S
1989
Long-term treatment with active vitamin D (α-calcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure.
Diabetes Res
11
:
141
147

30

Ljunghall
S
,
Lind
L
,
Lithell
H
,
Skarfors
E
,
Selinus
I
,
Sorensen
OH
,
Wide
L
1987
Treatment with 1-α-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance: a prospective randomized double-blind study.
Acta Med Scand
222
:
361
367

31

Holick
MF
2004
Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis.
Am J Clin Nutr
79
:
362
371

32

Visser
M
,
Deeg
DJ
,
Lips
P
2003
Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam.
J Clin Endocrinol Metab
88
:
5766
5772

33

Scragg
R
,
Sowers
M
,
Bell
C
2004
Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey.
Diabetes Care
27
:
2813
2818